10-K: Werewolf Therapeutics Reports 2024 Financial Results and Provides Business Update

Werewolf Therapeutics details its 2024 financial performance and outlines key developments in its clinical programs.

Summary

• Werewolf Therapeutics reported a net loss of $70.5 million for the fiscal year ended December 31, 2024, and had cash and cash equivalents of $111.0 million as of the same date.
• The company is currently evaluating WTX-124 in a Phase 1/1b clinical trial and expects full enrollment in the monotherapy dose expansion arm in the first half of 2025 and in the combination arm in the second half of 2025.
• A Phase 1/2 dose and regimen-finding clinical trial of WTX-330 is expected to begin in the first quarter of 2025.
• The company continues preclinical development of WTX-712, WTX-518, and WTX-921.
• Werewolf recognized $1.9 million in collaboration revenue from Jazz Pharmaceuticals in 2024 related to JZP898.
• The company expects its cash and cash equivalents will fund operations through at least the second quarter of 2026.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress in its clinical programs, it is also experiencing significant losses and will need to raise additional capital. The sentiment is neutral, reflecting both the potential for future success and the challenges the company faces.

Positives

• WTX-124 is showing promising clinical activity in ongoing trials.
• WTX-330 is advancing to a Phase 1/2 clinical trial.
• The PREDATOR platform continues to generate new product candidates.
• The company has alignment from the FDA on the comparability path for WTX-330 manufacturing.
• The company has a strong cash position to fund ongoing clinical trials and preclinical development.

Negatives

• The company has a history of net losses and expects to continue incurring losses.
• The company has no products approved for commercial sale and has not generated any revenue from product sales.
• The company is dependent on the success of its initial INDUKINE molecules, which are in the early stages of development.
• The company's approach to the discovery and development of product candidates based on its PREDATOR platform is unproven.
• The company relies on third parties to manufacture its product candidates, which could lead to delays or supply issues.

Risks

• The company will need to obtain substantial additional funding to finance its operations.
• The company may encounter substantial delays in the commencement or completion of its clinical trials.
• The company faces substantial competition from other companies developing immunotherapies.
• The company relies on its license agreement with Harpoon Therapeutics, Inc. for patent rights.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company expects its existing cash and cash equivalents will be sufficient to fund its operational expenses and capital expenditure requirements through at least the second quarter of 2026. The company plans to meet with regulatory authorities to discuss potential registrational pathways in the second half of 2025 and to release a monotherapy and combination therapy clinical data update in the fourth quarter of 2025.

Management Comments

• Management expects to continue to incur substantial and increasing expenses and net losses for the foreseeable future.
• Management has broad discretion in the application of the company's cash and cash equivalents.

Industry Context

The announcement highlights Werewolf's efforts to develop novel immunotherapies for cancer, a competitive field with significant unmet medical needs. The company's PREDATOR platform and INDUKINE molecules represent a unique approach to stimulating the immune system within the tumor microenvironment.

Comparison to Industry Standards

• Werewolf Therapeutics is competing with companies like Anaveon AG, Ascendis Pharma A/S, Asher Biotherapeutics, Inc., Aulos Bioscience, Inc., BioNTech SE, Cue Biopharma, Inc., DEKA Biosciences, Inc., Merck & Co., Inc., Medicenna Therapeutics Corp., Mural Oncology PLC, F. Hoffmann-La Roche AG, Synthekine, Inc., and Xilio Therapeutics, Inc. in the IL-2 space.
• In the IL-12 space, Werewolf Therapeutics is competing with companies like Sanofi S.A. (Amunix), DEKA Biosciences, Inc., DragonFly Therapeutics, Inc., Juno Therapeutics, Inc. (Bristol-Myers Squibb Company), Mural Oncology, OncoSec Medical Incorporated, Philogen S.p.A., Sonnet BioTherapeutics, Inc., Turnstone Biologics Corp. (partnered with Takeda Pharmaceutical Company Limited), Xilio Therapeutics, Inc., and Zymeworks Inc.

Related Party Transactions

• The company entered into a sublease agreement with Crossbow Therapeutics, Inc., for which entities affiliated with MPM Capital are also beneficial owners. Luke Evnin, Ph.D., the chair of the company's board of directors, co-founded MPM Capital and serves as Managing Director of MPM Capital. Briggs Morrison, who serves on the company's board of directors, serves as Executive Partner of MPM Capital and Chief Executive Officer of Crossbow.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures if the company is unable to raise additional capital.
• Patients may benefit from the development of new cancer therapies.
• Suppliers and creditors may be affected by the company's financial performance.

Next Steps

• Continue clinical trials for WTX-124 and WTX-330.
• Advance preclinical programs for WTX-712, WTX-518, and WTX-921.
• Seek potential registrational pathways for WTX-124.
• Release clinical data updates for WTX-124.
• Initiate Phase 1/2 trial for WTX-330.

Key Dates